Table 1 Correlations of miR-22 expression with the clinicopathological features of primary gastric cancer

Age (years)

98

62.8 ± 23.2

62.1 ± 23.9

NS

Gender

Male

62 (63.3)

25 (40.3)

37 (59.7)

NS

Female

36 (36.7)

15 (41.7)

21 (58.3)

Histopathological type

Intestinal type

pap

5 (5.1)

2 (40.0)

3 (60.0)

NS

tub1

20 (20.4)

9 (45.0)

11 (55.0)

tub2

25 (25.5)

8 (32.0)

17 (68.0)

Diffuse type

por1

15 (15.3)

6 (40.0)

9 (60.0)

NS

por2

33 (33.7)

15 (45.5)

18 (54.5)

Tumor depth (pT)

pT1

40 (40.8)

20 (50.0)

20 (50.0)

NS

pT2

30 (30.6)

10 (33.3)

20 (66.7)

pT3

20 (20.4)

8 (40.0)

12 (60.0)

pT4

8 (8.2)

2 (25.0)

6 (75.0)

Lymph node metastasis (pN)

pN0

50 (51.0)

27 (54.0)

23 (46.0)

0.02

pN1

20 (20.4)

8 (40.0)

12 (60.0)

pN2

15 (15.3)

4 (26.7)

11 (73.3)

pN3

13 (13.3)

1 (7.7)

12 (92.3)

Distant metastasis (pM)

pM0

86 (87.8)

39 (45.3)

47 (54.7)

0.01

pM1

12 (12.2)

1 (8.3)

11 (91.7)

pStage

I

50 (51.0)

29 (58.0)

21 (42.0)

0.02

II

15 (15.3)

5 (33.3)

10 (66.7)

III

20 (20.4)

5 (25.0)

15 (75.0)

IV

13 (13.3)

1 (7.7)

12 (92.3)

Lymphatic invasion

Negative

45 (45.9)

17 (37.8)

28 (62.2)

NS

Positive

53 (54.1)

23 (43.4)

30 (56.6)

Venous invasion

Negative

68 (69.4)

23 (33.8)

45 (66.2)

NS

Positive

30 (30.6)

17 (56.7)

13 (43.3)

Hematogenous recurrence

Negative

78 (79.6)

32 (41.0)

46 (59.0)

NS

Positive

20 (20.4)

8 (40.0)

12 (60.0)